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The recently published study ICTUS did not present significant difference between groups treated within invasive or conservative arms in terms of mortality, reinfarction or rehospitalization rate for period 1 and 3 year follow-up (22.7% versus 21.2%, p = 0.33). There was observed an increased incidence of early myocardial infarction (15% versus 10%, p = 0.005) among invasive managed patients. During initial hospitalization, however, 76% of patients in the invasive group and 40% of patients scheduled for conservative treatment underwent revascularization procedure (Hirsh A et al., 2007) . Similarly, meta-analysis of more than 4500 patients from randomized trials has suggested that routinely indicated coronary angiography compared with more conservative strategy was associated with increased incidence of early mortality (1.8% vs. 1.1%, p = 0.007) and combined endpoint of death and reinfarction (5.2 % vs. 3.8%, p = 0.002). Long term monitoring however, favored an invasive strategy with a reduction of death and reinfarction (12.2% versus 14.4%, p = 0.001) (Mehta SR et al., 2005) . Some clinical trials were able to document benefit of invasive strategy in NSTE-ACS patients with an increased troponin level in the beginning, but not at its normal levels (Diderholm E et al., 2002 , Lagerqvist B et al., 2006 . In a recently published meta-analysis of more than 8300 patients with NSTE-ACS, there has been documented benefits of timely invasive procedure compared with conservative management in order to reduce mortality (4.9% vs. 6.5%, p = 0.001), nonfatal myocardial infarction (7.6 % vs. 9.1%, p = 0.012) over a 2 year follow-up period, without increasing risk of myocardial infarction within 1 month (Bavry AA et al., 2006) . Reduction of mortality rate in the early invasive strategy was present during the 5-year follow-up periods in FRISCO II and RITA 3 trials as well Lagerqvist B et al., 2006 ).
RISC score
As has been pointed out previously, NSTE-ACS is a heterogeneous group of diseases. Coronary angiography can reveal severe stenosis of one or more coronary arteries, narrowing of the left main coronary artery, presence of intracoronary thrombi (FRISC II investigators, 1999; Kovar F et al., 2003 Kovar F et al., , 2004 . These facts reflect current recommendations of the European Society of Cardiology (ESC), which emphasize the need for early (and repeated as necessary) risk stratification in patients with NSTE-ACS (Bassand JP et al., 2007) .
GRACE score
The GRACE (Global Registry of acute coronary events) risk score takes into account age, heart rate, systolic blood pressure, serum creatinine level, Killip class on admission, need for resuscitation for cardiac arrest, presence of ST segment depression and increased values of of myocardial necrosis markers (Eagle KA et al., 2004; Fox KA et al., 2006) . GRACE score is based on the analysis of a large unselected population from an international registry of all ACS (STEMI and NSTEMI). Evaluated risk factors show independent predictive value for both hospital and 6-month mortality (tab. 1).
TIMI score
The TIMI (Thrombolysis in myocardial infarction) risk score assesses anamnestic variables (age ≥ 65 years, ≥ 3 risk factors of ischemic heart disease, known coronary artery stenosis > Table 2 . TIMI (Thrombolysis in myocardial infarction) risk score parameters 50%, aspirin therapy in the last 7 days and the actual presence of severe angina within 24 hours, ST segment deviations > 0.5 mm and increased laboratory markers of necrosis (Antman EM et al., 2000) . TIMI score is then the sum of individual items (value 0-7) (tab. 2). Its advantage is simplicity, but has not so high predictive accuracy as a comprehensive GRACE score ( Figure 1 ).
Correlation between coronary angiography findings and the TIMI risk score level
In a retrospective study, we investigated contribution of early risk stratification to the invasive management timing. 
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• arteria coronaria dextra -RCA > 75% • multivessel coronary artery disease -stenosis ≥ 3 -coronary arteries There were more coronary arteries stenoses identified with increasing TIMI risk score ( Figure 8 ). In age range ≥ 65 years in comparison with age bellow 65 year, there were more coronary arteries stenoses among patients with intermediate risk. This relationship was even more pronounced in patients in high TIMI risk score group (Figure 9 and 10). 
Indication and timing of invasive diagnostics
Depending on the risk score level, we can make decisions for the indication of invasive diagnostic and its timing in patients with NSTE-ACS in three modes (urgent, early invasively and elective) (Bassand JP et al., 2007) :
Urgent invasive strategy
It is indicated within 2 hours in patients with high risk score. This strategy is taken in to account particularly in patients with: a. Refractory angina b. Recurrent angina despite intensive pharmacologic treatment with presence of deep (≥ 2 mm) ST segment depression or deep negatives T waves on ECG c. Symptoms of heart failure or hemodynamic instability (incipient signs of shock) d. Serious arrhythmias (ventricular fibrillation or ventricular tachycardia)
Early invasive strategy
This strategy is considered in NSTE-ACS patients with high risk of serious ischemic events. Coronary angiography should be performed within 72 hours in this group.
(%)
www.intechopen.com These are patients presenting with: a. elevated troponin levels b. dynamic ST segment or T waves changes (≥ 0.5 mm) c.
diabetes mellitus d. reduced renal function (GFR <1 ml / s) e.
reduced left ventricular ejection fraction <40% f.
angina pectoris early after myocardial infarction g. angina pectoris within 6 months after coronary intervention (PCI) h. history of coronary artery bypass grafting (CABG) i. medium or high risk GRACE score
Conservative (elective) strategy
It is indicated in those patients who meet all the following criteria: Are free of: a. Recurrence of angina pectoris b. Symptoms of heart failure c. Major arrhythmias d. Changes in both initial and second ECG (after 6-12 hours) e. Elevated troponin levels (at entrance examinations and even after 6-12 hours) Low risk, as assessed by GRACE or TIMI scores, supports the decision making for a conservative treatment. These patients should undergo an exercise test before hospital discharge and coronary angiography in case of inducible ischemia. Risk stratification of ACS patients (as recommended by the ESC) is now clearly recommended to identify patients with moderate to high risk of serious cardiovascular complications, who benefit most from both early invasive diagnosis and subsequent coronary arteries revascularization. In so selected risky ACS group coronary angiography has to be performed during index hospitalization.
Effect of early treatment strategy on long-term outcomes in NSTE-ACS
Because invasive diagnosis plays an important role in the management of NSTE-ACS, we decided to analyze the clinical course of patients who have been made coronary angiography at the beginning and by finding subsequently revascularization, and also in those patients who refused invasive testing (Kovar F et al., 2007) .
Patients and methods
Prospective analysis of consecutive patients admitted to our clinic with a diagnosis of unstable angina or myocardial infarction without ST segment elevation. All patients received comprehensive standard (according to current recommendations) pharmacologic therapy. Within 48 hours was performed coronary angiography and further revascularization therapy if appropriate. Invasive diagnosis was not performed in patients who refused this procedure. Initial coronary angiography record was analyzed according to location and type of coronary stenosis (A, B, C), closure of coronary artery was evaluated separately. Lesion type A: a short concentric stenosis, easily accessible, less calcified, without thrombus, without side branch involving (success rate of intervention> 85%, low risk) Lesion type B: tubular 10 to 20 mm long, eccentric, with the presence of calcifications, involving ostium of coronary artery, bifurcation stenosis, presence of thrombus (intervention success rate 60-85%, moderately high risk) Lesion type C: diffuse stenosis> 20 mm, extremely coiled proximal segments, bifurcation lesions with the impossibility to access a lateral branches (success rate of intervention <60%, high risk) (Figure 12 a,b,c). During the one-year follow-up period there were assessed mortality rate, need for repeated hospitalization for ACS or revascularization and left ventricular ejection fraction (LVEF). These endpoint variables were evaluated in four groups of patiens who: 1) underwent percutaneous coronary intervention (PCI) or 2) surgical revascularization (CABG), 3) after angiography were treated conservatively or 4) refused invasive diagnostics in the beginning.
Statistical analysis
Any analysis of the effectiveness of the treatment was made in four groups of patients: PCI, CABG, conservative treatment and conservative treatment without initial invasive diagnosis. Two-sided Fisher's exact test in the modification of 2 x 4 was used to test hypotheses about the same effect of therapies. χ 2 test were used for a posteriori analysis of categorical variables. As statistically significant we considered differences at significance level of P < 0,05.
Results
During the reporting period were for UA and NSTEMI admitted 183 patients, of which 109 were men aged 35-84 (mean ± SD: 55,9 ± 11,6) years and 74 women aged 44-86 (mean ± SD: 66; 5 ± 12.0) years. History and clinical variables are shown in table 3. Evaluated population of patients has been at high risk for the presence of cardiovascular risk factors and history of cardiovascular disease: more than 65% patients had hypertension, 37.7% had a myocardial infarction, in nearly 20% was already performed a revascularization of coronary arteries in the past, 9.8% had stroke, hypercholesterolemia was present in 77% and diabetes mellitus in 25.7% of all patients. Early after hospital admission, 171 patients (93.4%) underwent coronary angiography and 12 (6.6%) patients refused invasive diagnostics (they were also treated conservatively). There was found in 7.6% of patients closure of coronary arteries, advanced atherosclerotic coronary artery stenosis (stenosis B and C) were evaluated in 67.8% patients on the initial angiography. Frequency of significant coronary arteries stenosis (ramus interventricularis anterior, ramus circumflexus, right coronary artery) was similar (37.4%, 32.8%, respectively 22 %), significant impairment of left main coronary artery was present in 7% of patients. 
Objective
The aim of this analysis is to provide an assessment of management of patients with NSTE-ACS in Slovakia in 2008 year and to assess compliance of fair practice and official recommended guidelines for diagnosis and treatment of ACS without ST segment elevations. The source data for analysis were drawn from the registry of acute coronary syndromes SLOVACS (Kovar F et al., 2010) .
Methods
SLOVACS registry is dedicated to both systematic data collection and subsequent analysis of ACS in Slovakia since 2007 year. This registry is organizationally arranged by Slovak Society of Cardiology (SKS) and National Health Information Centre (NHIC) (Studencan M et al., 2008) . Data on patients with acute coronary syndrome are recruited from sheets of ACS, which are completed and electronically transmitted to the NHIC by physicians from different departments (internal, cardiology, intensive care units, coronary units), where is the patient hospitalized with a diagnosis of ACS. This activity is supervised by the special regional coordinators.
In this particular analysis we evaluated data results in patients with NSTE-ACS and nonspecified ACS. If the detailed and clear ECG diagnosis and accurate categorization of ACS at admission was not possible, this ACS was marked like non-specified ACS (presence of left bundle branch block, after repeated myocardial infarction, repolarization changes in left ventricular hypertrophy).
In NSTE-ACS population were assessed selected history variables, age and gender of patients. There was made an analysis of given therapy, with special attention to invasive diagnosis of ACS and revascularization therapy (PCI or surgical). It was also evaluated hospital mortality and subsequent analysis of the causes of death.
Statistical analysis
Descriptive statistics were calculated for patient groups of men and women in the categories of UA / NSTEMI-ACS and non-specified ACS. Averages and standard deviations (SD) were calculated for continuous variables and for categorical variables were calculated frequency distribution or percentage was used respectively. To estimate the statistical significance of differences, Student's t-test for continuous variables and Fisher's exact test for categorical variables were used. For statistically significant differences the significance level of P < 0,05 was determined. Statistical analysis was performed in SPSS, Windows version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
There were reported to NHIC 3047 hospitalization for NSTE-ACS and 799 hospitalizations for non-specified ACS during period 1.1. 2008 -31.12.2008 . For all subtypes of ACS, women were on average older than men and men diagnosed with NSTE-ACS were significantly older compared with a group of men in the STEMI-ACS (66 ± 12 vs. 61 ± 12, P < 0,001). Tab. 6 shows the proportion of patients in different types of ACS, taking into account age and sex. Table 6 . Distribution of ACS by type, age and sex a P < 0,001 men vs women, b P < 0,001 men with STEMI vs men with NAP/NSTEMI, ACSacute coronary syndrome, STEMI -acute coronary syndrome with ST segment elevation, UA / NSTEMI -Unstable angina pectoris / myocardial infarction without ST segment elevations
Number of cases Mean age (years± SD)

Anamnestic data
Each patient was systematically assessed with respect to the evidence of hypertension, diabetes mellitus type I or II, history of stroke. As is apparent from the graphs 12 and 13, in both types of ACS was significantly often present arterial hypertension (80.1% respectively 78.3%) and diabetes mellitus type II (30.3% respectively 27.1%) and 12.1% of patients has history of stroke (Figures 13 and 14) . Occurence of concominat diseases in patinens with non-STE-ACS was similar in both SLOVACS registries 2007 and 2008 years (Figure 15 ).
Revascularization therapy
Among 3047 patients with NSTE-ACS coronary angiography was performed in 943 patients (30.9%) during index hospitalization, 799 patients (26.2%) were sent to catheterization laboratory from other institutions. Of the 799 patients with non-specified ACS was performed coronary angiography in 284 patients (35.5%). To invasive diagnosis were referred 187 patients (23.4%) from other hospitals (without catheterization facilities). Percutaneous coronary intervention (PCI) was performed in 409 patients (13.4%) with NSTE-ACS and 50 patients (6.3%) with non-specified ACS. During PCI was in NSTE-ACS implanted 370 intracoronary bar metal stents and 76 (20.5%) drug eluting stents. In nonspecific ACS patients were during intervention procedures implanted 111 stents, including 17 (15.3%) drug eluting stents. Surgical revascularization (CABG) was performed during hospitalization for NSTE-ACS in 165 patients (5.4%) or was scheduled electively for additional 128 patients (4.2%). Together was cardiac therapy planned for 293 patients (9.6%). In case of non-specific ACS were performed CABG immediately in 27 patients (3.5%), and planned later in 30 pts. (3.8%), together was cardiac revascularization indicated in 57 patients (7.3%). Other non-cardiac cause 3 (6.4%) 7 (11.3%) 0,049 4%) . These data are similar to data from other registries ACS (Polonski L et al., 2007) . There is even more serious situation in the indication of patients for invasive diagnosis among non-specified ACS group, which has highest hospital lethality (6%) in comparison with various types of ACS. These patients are often elderly, with more significant co morbidity, renal insufficiency (Lev EI et al., 2003) . From invasive diagnostic benefit most patients with high risk of cardiovascular complications. Patients with UA / NSTEMI represent a heterogeneous group of diseases with potentially serious both in-hospital course and long-term prognosis. As was found by the results of SLOVACS registry 2008, there is frequent co morbidity with high presence of hypertension and diabetes mellitus type II in patients with NSTE-ACS. Hospital mortality was 3.6%, in patients with NSTE-ACS and 6% in non-specified ACS, respectively. SLOVACS registry data confirm excellent acceptance of recommendations, relating to the combined pharmacological treatment of NSTE-ACS with a high administeration rate of dual antiplatelet therapy, beta blockers, angiotensin converting enzyme inhibitors, anticoagulant therapy (UFH and LMWH) and statins. In the management of NSTE-ACS would be desirable more frequent application of platelet glycoprotein IIb / IIIa inhibitors, especially in high-risk patients. Unsatisfactory low is the indication rate for invasive diagnostic procedures and revascularization treatment. Only 30.9% of patients with UA / NSTEMI and 23.4% with non-specified ACS have performed selective angiography during the initial hospitalization. PCI was performed in 13.4% patients with NSTE-ACS and only 6.3% patients with non-specified ACS. SLOVACS registry results suggest the need for increased concentration of attention on a consistent risk stratification of patients with NSTE-ACS. In the case of medium or high risk of cardiovascular complications and unfavorable course, patients should be indicated for selective angiography and depend on finding, further coronary artery revascularization. Invasive diagnosis in these patients has to be conducted during the index hospitalization for NSTE-ACS.
Pharmacological treatment
Impact of bleeding complications on the prognosis of NSTE-ACS
In most cases a vulnerable plaque (with rupture or erosion) in the coronary artery with the presence of intracoronary platelets rich thrombus represents pathophysiologic basis of ACS.
The key basic treatment regimen for NSTE-ACS is, therefore, antiplatelet therapy (mostly dual) and application anticoagulants agents (unfractionated heparin, low molecular weight heparin, fondaparinux, and direct thrombin inhibitors). In patients treated with PCI are often administered platelet IIb / IIIa receptor blocker. These combined and effective antithrombotic approaches significantly reduce the incidence of thrombotic complications in NSTE-ACS, but are often associated with an increased risk of bleeding. Recently, systematic attention is paid to the impact of bleeding on prognosis in patients with NSTE-ACS.
Occurrence
Bleeding complications can achieve varying degrees of severity. The most frequently used assessment is according to the TIMI (Thrombolysis in myocardial infarction) and GUSTO (Global utilization of streptokinase and t-PA for occluded coronary arteries) criteria (Table  11 ) (Antman EM et al., 2005; GUSTO investigators, 1993) . The incidence of major bleeding complications in the treatment of NSTE-ACS is in the range 2-15% (OASIS-2 investigators, 1999; Ferguso JJ et al., 2004; Bhat DL et al., 2004) . Frequency of bleeding is influenced by excessive dose antithrombotic medications, antithrombotic agents alternation (switching), presence of renal dysfunction, higher age of the patient and female gender (Alexander KP et al., 2005; Collet JP et al., 2005) . European register GRACE (Global registry of acute coronary events) has identified additional independent predictors of major bleeding complications in NSTE-ACS patients (Table 12 ) (Moscucci M et al., 2003) . (Moscucci M et al., 2003) (Figure 19 ).
*After adjustment for comorbidities, clinical presentation, and hospital therapies **p<0.001 for differences in unadjusted death rates Fig. 19 . Association of major bleeding and an increased risk of hospital death in ACS patients
In REPLACE (Randomized Evaluation of PCI linking angiomax to reduced clinical events) -2 study, patients with major bleeding had 30 times higher risk of death during the 30-day monitoring in comparison with patients without such bleeding complications (5.2% vs. 0.2%; p <0.001). Moreover, the multivariate analysis identified a major bleeding as the third strongest predictor (with renal dysfunction and heart failure) of 1-year mortality (OR 3.53, 95% CI 1.91 to 6.53, p <0.0001) (Stone GW, 2004) . Analysis of more than 26 000 patients from ACS studies GUSTO (Global utilization of streptokinase and t-PA for occluded coronary arteries) IIb, PURSUIT (Platelet glycoprotein IIb / IIIa in unstable angina: receptor suppression using INTEGRILIN therapy) and PARAGON (Platelet IIb / IIIa antagonist for the reduction of acute coronary syndrome events in a global organization network) shows a link between 30-day mortality and severity of bleeding, irrespectively of invasive procedures ( Figure 20 ) (Rao SW et al., 2005) . Another meta-analysis (34 000 patients) from OASIS (Organization to ASSESS strategies in acute ischemic syndromes) registry, OASIS-2 study and CURE (Clopidogrel in unstable angina to Prevent Recurrent Events) study confirmed that serious bleeding is a strong independent predictor of mortality, myocardial infarction and stroke (Table 13 ) (Eikelboom JE et al., 2006) . Interesting results were shown by a 10-year retrospective analysis of 11 000 patients treated with PCI (Kinnaird TO et al., 2003) . Major bleeding was confirmed as an independent risk factor for hospital mortality (OR 3.5, 95% CI 1.9 to 6.7, p = 0.001). Patients with bleeding complications had significantly higher incidence of Q-wave myocardial infarction (1.2% vs. 0.2%, p <0.001), non Q-wave myocardial infarction (30.7% vs. 11.8%, p <0.001) and needs for repeat revascularization (1.9% vs. 0.3%, p <0.001) compared with the group without bleeding. Significantly increased risk of death was associate with bleeding by TIMI criteria rated as small as well (1.8% vs. 0.6%, p <0.001) ( Figure 21 ). 6% 6.46 (3,54-11,79) <0.0001 Table 13 . Effect of bleeding on the clinical course OASIS = Organization to assess strategies in acute ischemic syndromes, CURE = Clopidogrel in unstable angina to prevent recurrent events Unambiguous confirmation of the negative impact of bleeding on the both early and longterm prognosis of patients with NSTE-ACS was brought by randomized trial OASIS-5 (Yusuf S et al., 2006) . This clinical study compared the effect of fondaparinux and enoxaparin in the treatment of more than 20 000 patients with NSTE-ACS. Although the primary efficacy endpoint (incidence of death, myocardial infarction or refractory ischemia to day 9) was similar in both groups (5.8% vs. 5.7%, p = ns), treatment with fondaparinux was associated with significantly lower incidence of bleeding complications (2.2% vs. 4.1%, p <0.001). Net clinical benefit, expressed the occurrence of death, myocardial infarction, Table 14 . Effect of bleeding to day 9 at 30 and 180-day course of patients with NSTE-ACS OASIS = Organization to ASSESS strategies in acute ischemic syndromes, stroke = stroke, NSTE-ACS = acute coronary syndrome without ST segment elevation refractory ischemia or major bleeding was more favorable in fondaparinux group (7.3% vs. 9.0%, p <0.001). Patients with significant bleeding to 9 day, had during a long-term (30 and 180 days) follow-up in the OASIS-5 study higher cumulative risk of mortality, myocardial infarction and stroke. This increased cumulative risk was present even in group of patients with a small bleeding (Table 14 , Figure 22 , 23, 24) (Budaj A et al., 2006) . Fig. 24 . Increase risk of stroke in patients with severe bleeding at day 9 (all pts at day 30 resp. day 180)
The mechanisms for worsening clinical course
There are postulated several mechanisms in connection with bleeding that could worse clinical course in NSTE-ACS (Table 15 ). Serious consequence of bleeding is interruption of antithrombotic therapy. Clinically significant bleeding actually required discontinuation of anticoagulant and antiplatelet therapy until resolution. In the case of small transition bleeding is often possible to continue this therapy (Bassand JP et al., 2007) . Application of blood transfusion improves the prognosis of elderly patients with acute myocardial infarction and hematocrit <30% (Wu WC et al., 2001) . However, in the hematocrit values > 33% there was not demonstrated the usefulness of a blood transfusion.
By contrast, in several clinical trials and meta-analysis, the administration of blood transfusion was associated with increased mortality, higher incidence of myocardial infarction and refractory ischemia (Sabatine MS et al., 2005; Rao SW et al., 2004) (Figure 25 ).
Adjusted for baseline characteristics, bleeding and transfusion propensity and nadir hematocrit Fig. 25 . Association of blood transfusion with an increased 30-day mortality in UA/NSTEMI patients On the worsening clinical course in patients with NSTE-ACS after transfusion administration may participate: a. erythrocyte damage b. influence the metabolism of NO in blood storage c. impaired release of oxygen from hemoglobin in the reduction content of 2,3difosfoglycerate in erythrocytes d. increase inflammatory mediators (Fransen SV et al., 2008) Accurate cut-off level of hemoglobin and hematocrit for indication of blood transfusion in patients with NSTE-ACS are not provided. According to current recommendations of the European Society of Cardiology transfusion is not indicated for hemoglobin> 80g / l or hematocrit> 25%, provided that anemia is a hemodynamically well tolerated (Bassand JP et al., 2007) .
Prevention of bleeding complications
Given the demonstrated risk of severe clinical events associated with bleeding and administration of blood transfusions, it is extremely important to use in patients with NSTE-ACS all available measures in bleeding prevention. It is necessary to focus particularly on:
• choice of safe drug (fondaparinux in OASIS-5 study) • appropriate dosage (taking into account age, gender, creatinine clearance) • duration of antithrombotic therapy • timing of early invasive treatment • choice of arterial access • combination of anticoagulant and antiplatelet therapy to choose only by certified indications Prevention of bleeding complications is also important in terms of reducing hospital costs for treatment of NSTE-ACS. As shown by economic analysis of the GUSTO IIb study, with an increase in severity of bleeding, there is prolonged hospitalization and rising financial costs. Length of hospitalization for NSTE-ACS without bleeding was 5.4 days, with slight bleeding 6.9, with moderate 15.0 days, and severe bleeding 16.4 days (p <0.01). Financial cost of hospitalization in each group significantly increased as follows: 14 282 USD vs. 21 674 USD vs. 45 798 USD vs. 66 564 USD (p <0.01) (Rao SV et al., 2008) .
Conclusion
In addition to a comprehensive pharmacologic treatment of NSTE-ACS, which includes the combined antiplatelet regimens (aspirin, clopidogrel, platelet receptor IIb / IIIa blockers) and effective anticoagulant therapy, plays an important role early invasive diagnosis and by finding subsequent coronary artery revascularization. From invasive procedures benefit most high risk patients with NSTE-ACS, who undergoing PCI. Early invasive strategy is for this risk group of patients safe and is associated with long-term favorable clinical course and substantially influence prognosis. There is very important in NSTE-ACS patients risk stratification at the beginning and according to the assessed risk scores subsequent decision for urgent or early invasive strategy. In low-risk NSTE-ACS is indicated stress test and in case of inducible ischemia is than followed by coronary angiography before hospital discharge. Patients with NSTE-ACS represent a risk population with an increased incidence of ischemic and bleeding complications. Bleeding events significantly affect both short and long-term prognosis of patients with NSTE-ACS. This is why it is necessary in the global risk stratification of NSTE-ACS a careful assessment of the risk of bleeding. Balanced assessment of the risk for both thrombotic and bleeding complications allows then to select optimal diagnostic and therapeutic management of patients with NSTE-ACS. 
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